leisure time -WSS

leisure time

author：knowledge 2025-09-30 23:06:37 - browse：6

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: Bluebird, CVS, Contineum

focus

WSS

Apple Vision Pro: A first look at health apps on the new VR headset

UnitedHealth increases loan offers after Change Healthcare outage

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Baby aspirin cuts fat buildup in liver disease patients, in small study

General Catalyst, Summa Health deal will turn on physician buy

New Ultima Genomics DNA sequencer can read genome for $100

explore

leisure time

leisure time

What does generative AI mean for health care? We asked experts

What we need to know about Arena Bioworks

Walensky prepares to leave CDC — and Congress — behind

Vertex non

Medical leaders decry Supreme Court decision on affirmative action

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Medical records are filled with copy

Health AI adoption puts security, privacy startups on investors' radar

Wikipedia

Vertigo drug brings hope for rare neuron disorder, Niemann

Apple Vision Pro: A first look at health apps on the new VR headset

Physicians and social media: If you see something, say something?

Time to name cancers by genetics, not organ of origin, expert says

App could help diagnose ear infections more accurately — and at home

Nurses recount patients attacks

explore

hotspot

focus

leisure time